Chapter 4: Examples of COVID-19 Real-World Evidence Studies


  1. Dagan N Barda N, Kepten E, et al. Protocol for: Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23. DOI: 10.1056/NEJMoa2101765. Published 2021. Accessed September 9, 2021.
  2. Rentsch CT, DeVito NJ, MacKenna B, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology. 2021;3(1):e19-e27. doi:10.1016/S2665-9913(20)30378-7
  3. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. New England Journal of Medicine. 2021;385(15):1355-1371. doi:10.1056/NEJMoa2110362
  4. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. The Lancet. 2021;398(10300):599-607. doi:10.1016/S0140-6736(21)00896-5
  5. Prats-Uribe A, Sena AG, Lai LYH, et al. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ. Published online May 11, 2021:n1038. doi:10.1136/bmj.n1038
  6. Wang C, Wang Z, Wang G, Lau JYN, Zhang K, Li W. COVID-19 in early 2021: current status and looking forward. Sig Transduct Target Ther. 2021;6(1):114. doi:10.1038/s41392-021-00527-1
  7. Mack CD, Osterholm M, Wasserman EB, et al. Optimizing SARS-CoV-2 Surveillance in the United States: Insights From the National Football League Occupational Health Program. Ann Intern Med. 2021;174(8):1081-1089. doi:10.7326/M21-0319